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Session 5
Part A: Instruments for Economic 
E l tiva ua on
J S ian anson
CHSD
Centre for Health Service Development
Types of Economic Evaluation   
A health treatment/ intervention may produce good health        
outcomes but at considerable cost…so we need to weigh 
up the cost in producing the level of health outcome.
Some approaches to economic evaluation in the health 
sector are:
• Cost of Illness Studies
• Cost Benefit Analysis
• Cost Effective Analysis
• Cost Utility Analysis
Types Of Economic Evaluation (Cont.)    
• Cost of Illness Studies
T t l l f ll d l t b i to a  va ue o  a  resources use  or os  y soc e y as a 
result of the condition or illness.
Direct Costs e g care and treatment costs . .    
Indirect Costs e.g. lost wages for patients and 
caregivers lost productivity,  
Intangible Costs e.g. value of pain and suffering and 
decreases in quality of life    
Does not assess the outcomes of particular interventions
Types Of Economic Evaluation (Cont )    .
C t B fit A l i• os  ene  na ys s
The resources used (costs) and the resultant benefits of 
different treatments/ programs are expressed in $ terms       . 
CBA assesses the ratio of cost to benefit
Monetary value of health and wellbeing outcomes are 
difficult to define – so is rarely used
However, does not consider health sector in isolation to 
th t ti ho er sec ors, so can answer ques ons suc  as:
whether resources should be allocated to programs 
preventing road injuries in young drivers or aimed at         
preventing institutional admission for the incontinent 
elderly living in the community.
Types Of Economic Evaluation (Cont.)    
• Cost Effectiveness Analysis (CEA): Compares different 
interventions (e.g. drugs, physiotherapy etc) for a particular 
condition/ illness. For comparison the outcome measures 
must be the same. It considers degree of outcome gained in 
relation to costs to achieve it in advising resource allocation          
and procurement decisions.
• Cost Utility Analysis: An extension of CEA but enables 
i f diff t t t t ith it diff tcompar sons o  eren  rea men s w  qu e eren  
outcomes. This is especially when interventions cause 
differences in the quantity (survival) and quality of life . It does 
this through combining these in the common metric of the 
Quality Adjusted Life Year. The costs data for achieving a 
QALY mean that different interventions for the same illness/ 
conditions can be compared as can interventions for other 
conditions. It can be used to assess whether drugs should be 
listed on PBS and to guide resource allocation decisions.        
Cost Utility and Health Indexes
Possible Outcomes in Economic Evaluation
1. The outcomes of treatment A and B are the same for all 
outcome measures including HRQOL (no difference )
2 All t i i t t t A d t.  ou comes are super or n rea men   compare  o 
treatment B (clearly A preferred)
B t h t d d ifu  w a  o we o 
3A. For Treatment A the HRQOL outcomes are better, but 
th t h i lo er ou comes suc  as surv va  are worse
or
3B. Outcomes differ by health dimension on the HRQOL 
measure between treatments A and B – one may improve 
physical functioning the other mental how do we weigh ,    –     
these up?
EuroQol EQ-5D 
• MOBILITY
– I have no problems in walking about 
– I have some problems in walking about 
– I am confined to bed 
• SELF-CARE
I h bl ith lf–  ave no pro ems w  se -care 
– I have some problems washing or dressing myself 
– I am unable to wash or dress myself 
• USUAL ACTIVITIES (e g work study housework family or leisure  . . , , ,    
activities)
– I have no problems with performing my usual activities 
– I have some problems with performing my usual activities 
– I am unable to perform my usual activities 
• PAIN/ DISCOMFORT
– I have no pain or discomfort 
I have moderate pain or discomfort–       
– I have extreme pain or discomfort 
• ANXIETY/ DEPRESSION
– I am not anxious or depressed 
– I am moderately anxious or depressed 
– I am extremely anxious or depressed 
EQ 5D Exercise-  
A th 5 ti d th t• nswer e  ques ons an  en ra e your 
health on the visual analog scale (VAS).
R t ith d ti l l• a e a person w  severe emen a, arge y 
confined to chair, resides in nursing home, 
needs to be fed and dressed gets agitated if     ,    
needs to be moved, has bouts of pain
• Rate a person you know with a health problem         
of your choice
• Is there a health state worse than death?       
Example EQ-5D Life
Has 5 dimensions: mobility, self-care, usual activities, pain/ 
discomfort anxiety/ depression (please fill in your copy)
1.0
,       
3 levels of response are available for each dimension 1 = 
no problems 2 = some problems 3 = extreme problems ,    ,    
Thus a person with extreme anxiety may respond 1,1,1,1,3 
th di i ’ h lth t tacross ese mens ons = a person s ea  s a e
Community values/ ‘utilities’ have been ascertained for a 
range of these health states based on a scale 1 = best 
imaginable health state to 0 = worst imaginable health state 
(usually death) . 
Various methods may have been used to do this (Standard 
G bl Ti T d Off Vi l A l S l t )am e, me ra e , sua  na og ca e e c 0.0
Death
QALYs
• Need a generic health related quality of life measure that 
describes a range of health states between life and death 
e g EQ 5D has 5 dimensions or questions and 3 levels of. . -           
response possible. It thus has hundreds of health states 
(245) that can be described (this will vary by instrument).
• Each of these health states can be valued on a scale 
between 0 (death) and 1 (life) – usually using preference         
methods such as standard gamble or time trade off. This 
gives the utility value for each health state (more on this 
later).
• Thus improvement gained by a treatment can be classified 
th t i t t t i tion e same me r c, e.g. a rea men  moves ncon nence 
patients from a health state valued at .6 to .7 (this is their 
improvement in health related quality of life). 
QALYs
However this needs to be adjusted for their period of•           
survival/ life expectancy – lets say 10 years for the 
example of incontinence
• So the treatment has gained the patient one QALY 
(10*.10 = 1) for incontinence
• Costs data are added to this – lets say $10K per QALY           
for incontinence and this can be compared with the cost 
per QALY for a different treatment for incontinence or a 
treatment for asthma or diabetes    .
• It thus helps you to choose between various treatments 
for a condition or to compare the costs and benefits of 
t t t diti d d irea men s across con ons an  so may a v se 
resource allocation decisions
Multi attribute Utility Instruments-   
  
Country 
N. 
Items
N.  
Scales
 
Weight 
Combination 
rule 
 
Range * 
AQoL A t li 12 4 TTO M lti li ti 0 04 1 00us ra a  u p ca ve  .   .  
EQ5D Europe/UK 5 5 TTO Regression 0.59  1.00 
HUI3 Canada 12 8 VAS/SG Multiplicative 0.36  1.00 
15D Finland 15 15 VAS Additive +0.11  1.00 
SF6D US/UK 12 6 SG Additive +0.30  1.00 
N t 1 00 F ll h lth 0 00 D tho es: .  = u  ea , .  = ea
 
N t MAU i t t ( h lth i d ) l b do e:  ns rumen s or ea  n exes  can a so e use  as 
generic HRQOL measures
Methods for deriving value or utility of 
health states
• Visual Analog Scale: Refer handout and Slide 9. Really a 
ranking of health states from 0.00 to 1.00 rather than a 
utility as no preference or trade off made simple but,        –   
not preferred
• Magnitude Estimation: The respondent is asked to      
consider the distance of a health state from 1.00 (full 
health) – similar issues to VAS
• Time Trade Off: For any health state a person is asked 
how many years of life they are prepared to give up for a 
treatment that will return them to full health from this 
health state
Methods (Cont.)
St d d G bl F h lth t t i• an ar  am e: or any ea  s a e a person s 
presented with a treatment option that has 2 possible 
outcomes: the probability of either full health for the 
remainder of life (e.g. 0.90) or death (e.g. 0.10). Or they 
can choose not to have treatment and remain with the 
health state described for the rest of their life        
• Person Trade Off. The participant is asked to estimate 
the number of people with this health state that would 
have to be treated to make a treatment worthwhile (e.g. 
choose between extending life of 10,000 people in full 
health by 1 year against a treatment that extended the          
life of N people with this condition for 1 year)
Generally SG and TTO are the preferred methods       
Valuations
Remember the person with extreme anxiety? The result for this health state 
(11113) derived from EQ 5D = 0 42 whereas from another condition e g   -   .      .  
(11112) the valuation/ preference could be .69
By this method we have derived one total health score and thus can compare             
the valuations for different health conditions (burden) and of the effect of 
different treatments on a condition
Utility for urinary incontinence could be .6. If treatment improves this to .7 
over 10 years then the value of treatment =.10 * 10 = 1 QALY. If we add the 
costs of treatments to this then the treatment providing the lowest cost per 
QALY gained is preferred
As there is a common metric theoretically we can also compare different 
f diff di i QALY l bltreatments or erent con t ons:  eague ta es
Utility instruments: the basic assumptions
• If treatment improves the utility of a person from 0.40 to 0.50, a 
gain of 0.10, and she lives in this better health state for 10 
years there is a gain of 1 QALY (quality adjusted life year):,        -   
0.10 X 1 X 10 = 1 QALY
• Providing this same treatment to 10 people, each of whom lives 
for 1 year in better health, is equivalent to 1 QALY:
0.10 X 10 X 1 = 1 QALY
If i d f d th (0 00) d t d t f ll h lth•  a person s save  rom ea  .  an  re urne  o u  ea  
(1.00) and lives for 1 year there is a gain of 1 QALY
              
              
??? 0.00 0.20 0.40 0.60 0.80 1.00 
       
Health states Death Full health 
worse than 
death 
equivalent 
health state 
equivalent 
health state 
 
QALY LEAGUE TABLE  
R t i t i tt l t i ($1000/Q)• es r c  c gare e sa es o m nors 
• Anti-depressants in patients with major clinical 
d i ($3000/Q)epress on 
• Hypertension treatment elderly ($3000/Q)
• Pap smear screening @ 4 years ($16000/Q)
• Driver side airbag ($27,000/Q)
• Chemotherapy in 75yo women breast cancer 
($58,000/Q)
• Screening and treatment for HIV in low risk 
populations (1.5 mil/Q)
Which health care program is the 
?most cost-effective
• A new wheelchair for elderly
I lit f lif 0 1– ncreases qua y o  e = .  
– 10 years benefit
– Extra costs: $ 3,000 per life year
– QALY = Y (years) x V (Value/Q) = 10 x 0.1 = 1 QALY
– Costs are 10 x $3,000 = $30,000
– Cost/QALY = 30,000/QALY
• Special post natal care
– Quality of life = 0.8
– 35 years benefit  
– Costs are $250,000
– QALY = 35 x 0.8 = 28 QALY
Cost/QALY = 8 929/QALY–   ,
What implicit bias might be evident here?
(B hb h 2006)ussc ac  
Distribution of HRQoL utility scores by 
instrument
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Summary
Health indexes provide one total health score rather than scores across 
di i i h lth filmens ons as n a ea  pro e.
This combined with survival data can provide a measure called QALYS –
Quality Adjusted Life Years Saved    
When this is combined with cost data for the treatments it can be used for 
cost utility analysis to determine which treatment may be best to invest in 
cost per QALY–   . 
However some indexes used (EQ-5D, SF-6D ) are often brief and simple
measures of patient health status as compared with traditional health 
profiles. 
Approach may lack sensitivity when comparing 2 drugs for minor health 
problems preventative interventions chronic disease? (refer paper,  ,     
provided)
But cost utility analysis can provide estimates which can advise resource 
allocation and advise registration of drugs for PBS
Quality of life profiles and burden       
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Discussion
• How would you describe the burden of 
disease shown for the various groups
• Note these graphs reflect self – reported 
morbidity (illness) not clinical diagnosis     –
might there be a difference?
• In community/ household surveys who 
might not be included in these surveys?      
Burden of Disease  
• The previous slides show one can compare the burden 
of disease for particular health conditions by using a 
health status measure such as SF 36 The ABS has     - .    
produced such profiles for Australia. The profile for 
depression reflects a greater burden for this condition as 
contrasted with others (Slide 21) and as compared with 
people with no depression (Slide 22). Such profiles may 
i i h h l h i i i i l l bi dass st w t  ea t  pr or ty sett ng part cu ar y com ne  
with data concerning the prevalence of the condition.
Burden of Disease: DALYs   
• Another approach to quantifying burden of disease is the measure of           
Disability Adjusted Life Years (DALYs) . 
• DALYs are a summary  measure of the years of healthy life lost due 
to illness or injury One DALY = one lost year of healthy life DALYs   .         .  
are calculated as the sum of the years of life lost due to premature 
mortality (YLL) and the equivalent years of healthy life lost due to 
poor health or disability.
• DALYs are calculated as weighted combinations of 4 components
– Life expectancy
– Value of life at different ages
– The value of future time (3% annual discount rate)
– The value of avoiding disability  
• Thus for any condition you can calculate the number of DALYS 
which gives you a comparative estimate of the burden of disease 
for major health conditions in your population – and global 
comparisons can also be made
Burden of Chronic Diseases: Australia
1.CHD (mainly YLL)
2. Stroke
3. COPD
4. Depression (mainly YLD)
5 L C ( i l YLL). ung ancer ma n y 
6. Diabetes (about 50:50)
7 Arthritis (mainly YLD).   
Refer AIHW website: www.aihw.gov.au
Useful in that it includes disability as well as mortality in providing a 
f fpicture o  national health. Deaths data would ignore the impact o  
depression and disability.
May advise re priority setting at global and national levels, and be useful 
for international comparisons but is not particularly useful re resource 
allocation as it provides no information as to whether effective 
interventions are available and at what cost
There are numerous criticisms concerning the assumptions in the 
methodology (refer briefing sheet).
Health Outcomes and Funding: Some 
Issues
An extreme view might be to say only fund those 
interventions and health services that produce good health 
outcomes for their patients. Discuss!
While HO is an important aspect to consider with funding 
remember:
• social and economic determinants of health status and 
health outcome
i t i tti th• eas er o measure n some se ngs vs. o ers
• inherent conservatism may lessen innovation
i l ti l t i di id l• max ma  versus op ma  ou comes,  n v ua  versus 
community
• whose values? (the community’s experts or those of   ,     
patients with the condition?)
Materials
• 2* QALY internet briefing sheets
• 1* DALY internet briefing sheet    
• Copies of Slide 9
• EQ-5D in instrument kit
